Tarenflurbil: a shot on goal.
Aisen
Paul S
PS
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic / Q000592:standards / Q000706:statistics & numerical data; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005480:Flurbiprofen / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D058225:Plaque, Amyloid / Q000187:drug effects / Q000201:enzymology; D016896:Treatment Outcome
D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D005480:Flurbiprofen; D053829:Amyloid Precursor Protein Secretases